Two Indian Nationals Indicted in Florida for Counterfeit Ozempic Scheme

Two Indian nationals face charges in a counterfeit Ozempic scheme, with thousands of fake doses sold in the U.S. FDA warns of rising health risks.

Editorial Desk

September 30, 2026 One Min Read

POLICY WIRE — Miami, United States — Two Indian nationals have been charged in a major counterfeit Ozempic operation that allegedly involved smuggling fake weight-loss medication into the U.S. from China, according to court documents released this week.

Swapnadip Roy, 33, and Vicky Ramancha, 37, both based in Dubai and holding Indian citizenship, were indicted in the Middle District of Florida in 2025. They are accused of orchestrating an international scheme to distribute counterfeit Ozempic to U.S. distributors at lower prices, bypassing official pharmaceutical channels regulated by the FDA.

📄 POLICY WIRE WHITEPAPER PUBLISHED: PAKISTAN’S NATIONAL SECURITY POLICY PRIORITIES

👉 READ BY CLICKING HERE

Roy, who recently appeared in federal court after being extradited from Italy, faces multiple charges including conspiracy to defraud and smuggle counterfeit drugs. Ramancha remains at large. The scheme, which ran from July 2023 to April 2024, involved fake packaging and labels designed to mimic legitimate Ozempic, manufactured by Novo Nordisk. The FDA has issued warnings about the dangers of counterfeit GLP-1 medications, which require prescriptions for legal use.

Reporting by Policy-Wire (PW)

Author

Editorial Desk

Policy Wire is your go-to editorial hub for insightful perspectives and informed analysis on pressing policy issues, both regionally and globally. Over the years, Policy Wire has collaborated with leading international news agencies—including AFP, AP, Reuters, and others—to provide fact-based reporting and nuanced commentary. With a commitment to clarity and credibility, we aim to bridge the gap between complex policy debates and public understanding, ensuring that our readers stay informed on the issues shaping the world today.